Abhinav Jain Buys Shares of TLPH $TLPH

Key Points

  • Abhinav Jain bought 5,100 shares of Talphera, Inc. ($TLPH).
  • $TLPH last traded around $1.06.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Abhinav Jain, insider at Talphera, Inc. ($TLPH), bought 5,100 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Talphera, Inc. Stock Down 11.7%

Shares of Talphera, Inc. ($TLPH) traded around $1.06 on Thursday, down 11.7% for the day.

Last price$1.06
Market cap$61.77M
Forward P/E-4.86
Beta0.70
52-week low$0.50
52-week high$1.57
50-day MA$1.25
200-day MA$1.03
Current ratio4.29
Quick ratio4.08
Debt-to-equity0.45

Talphera, Inc. Earnings

EPS (ttm)-$0.23
Revenue (ttm)$1K
Net margin0%
Return on equity-143.36%
Next earningsNov 11, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$3.17
High target$3.50
Low target$3
Analysts covering3

About Talphera, Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

ExchangeNasdaqCM
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSan Mateo, CA
CEOMr. Vincent J. Angotti
Employees12

Get Talphera, Inc. alerts

New 13F filings, insider trades, and analyst moves on $TLPH, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.